Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00791271 · ClinicalTrials.gov registry record · Phase 1
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion
A Phase 1 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT00791271: Clinical Trial Phase 1 study, sponsored by M.D. Anderson Cancer Center.
NCT00791271 is a Phase 1 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00791271, a Phase 1 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The goal of the first phase of this clinical research study is to find the highest tolerable dose of decitabine and peginterferon alfa-2b that can be given in combination to patients with melanoma. The safety of this drug combination will also be studied. The goals of the second phase are to learn if decitabine and peginterferon alfa-2b combined can help to control melanoma, and to find out which doses are more effective and/or better tolerated.
Interventions
- DRUG Decitabine
- DRUG Pegylated Interferon Alpha-2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2008-09-02 |
| Est. Completion | 2015-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00791271
The ClinicalTrials.gov registry entry for NCT00791271 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Decitabine is the first listed.
NCT00791271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00791271 about?
NCT00791271 is a clinical study titled "Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion". The goal of the first phase of this clinical research study is to find the highest tolerable dose of decitabine and peginterferon alfa-2b that can be given in combination to patients with melanoma. The safety of this drug combination will also be studied. The goals of the second phase are to learn ...
What is the current status of trial NCT00791271?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2008-09-02. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00791271?
The interventions under investigation include: Decitabine (DRUG), Pegylated Interferon Alpha-2b (DRUG).
Who is sponsoring clinical trial NCT00791271?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.